- In June 2024, the Army Hospital (Research & Referral) in New Delhi, India, unveiled a cutting-edge skin bank facility, marking the first of its kind within the Armed Forces Medical Services. This groundbreaking initiative is designed to transform the treatment of severe burn injuries and various skin-related ailments for servicemen, servicewomen, and their families
- In October 2024, CUTISS AG, one of the leading life science companies specializing in tissue engineering therapy and regenerative medicine, announced the successful grafting of denovoSkin, its autologous bio-engineered dermo-epidermal skin graft, in a compassionate reconstructive procedure. This marks the company’s first case in the U.S. The procedure received authorization from the U.S. Food & Drug Administration (FDA) under a single-patient Investigational New Drug (IND) application and was carried out by the surgical team at Massachusetts General Hospital (MGH)
- In March 2024, the FDA approved the marketing of the Medline Autologous Regeneration of Tissue (ART) Skin Harvesting System, a groundbreaking handheld semi-automated device designed to harvest skin tissue from a healthy (donor) area of a patient's body and apply it directly to a wound where a skin graft is needed. Instead of using a blade to cut a sheet of skin, the device employs an array of thin needles to collect numerous small plugs of skin (micrografts). This innovative approach allows healthcare providers to carry out the harvesting and graft application process in a minimally invasive manner, utilizing local anesthesia and expanding the range of clinical settings suitable for this procedure beyond those typically used for conventional skin grafts
